0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Treatment in Psychiatry   |    
Psychiatric Clearance for Patients Started on Interferon-Alpha-Based Therapies
Francis E. Lotrich, M.D., Ph.D.
Am J Psychiatry 2013;170:592-597. doi:10.1176/appi.ajp.2013.12121572
View Author and Article Information

Dr. Lotrich has received research support from NIH, NARSAD, and the Dana Foundation.

From the Western Psychiatric Institute and Clinic, Pittsburgh.

Address correspondence to Dr. Lotrich (lotrichfe@upmc.edu).

Copyright © 2013 by the American Psychiatric Association

Received December 16, 2012; Revised January 30, 2013; Accepted February 04, 2013.

Extract

Figures in this Article

First Page Preview

View Large
/>
First page PDF preview
Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

+

References

Rosenberg  SD;  Goodman  LA;  Osher  FC;  Swartz  MS;  Essock  SM;  Butterfield  MI;  Constantine  NT;  Wolford  GL;  Salyers  MP:  Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness.  Am J Public Health 2001; 91:31–37
[CrossRef] | [PubMed]
 
Capuron  L;  Hauser  P;  Hinze-Selch  D;  Miller  AH;  Neveu  PJ:  Treatment of cytokine-induced depression.  Brain Behav Immun 2002; 16:575–580
[CrossRef] | [PubMed]
 
Donnelly  S:  Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma.  Oncol Nurs Forum 1998; 25:921–927
[PubMed]
 
Malaguarnera  M;  Di Fazio  I;  Restuccia  S;  Pistone  G;  Ferlito  L;  Rampello  L:  Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha.  Neuropsychobiology 1998; 37:93–97
[CrossRef] | [PubMed]
 
Trask  PC;  Esper  P;  Riba  M;  Redman  B:  Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions.  J Clin Oncol 2000; 18:2316–2326
[PubMed]
 
Schaefer  M;  Sarkar  R;  Knop  V;  Effenberger  S;  Friebe  A;  Heinze  L;  Spengler  U;  Schlaepfer  T;  Reimer  J;  Buggisch  P;  Ockenga  J;  Link  R;  Rentrop  M;  Weidenback  H;  Fromm  G;  Lieb  K;  Baumert  TF;  Heinz  A;  Discher  T;  Neumann  K;  Zeuzem  S;  Berg  T:  Escitalopram for the prevention of peginterferon-alpha-2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.  Ann Intern Med 2012; 157:94–103
[CrossRef] | [PubMed]
 
Lotrich  FE:  Major depression during interferon-alpha treatment: vulnerability and prevention.  Dialogues Clin Neurosci 2009; 11:417–425
[PubMed]
 
Janssen  HL;  Brouwer  JT;  van der Mast  RC;  Schalm  SW:  Suicide associated with alfa-interferon therapy for chronic viral hepatitis.  J Hepatol 1994; 21:241–243
[CrossRef] | [PubMed]
 
Zdilar  D;  Franco-Bronson  K;  Buchler  N;  Locala  JA;  Younossi  ZM:  Hepatitis C, interferon alfa, and depression.  Hepatology 2000; 31:1207–1211
[CrossRef] | [PubMed]
 
Castéra  L;  Constant  A;  Henry  C;  Couzigou  P:  [Psychiatric disorders during treatment of chronic hepatitis C].  Gastroenterol Clin Biol 2005; 29:123–133 (French)
[CrossRef] | [PubMed]
 
Castera  L;  Constant  A;  Henry  C;  Champbenoit  P;  Bernard  PH;  De Ledinghen  V;  Demotes-Mainard  J;  Couzigou  P:  Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C.  Aliment Pharmacol Ther 2006; 24:1223–1230
[CrossRef] | [PubMed]
 
Dinwiddie  SH;  Shicker  L;  Newman  T:  Prevalence of hepatitis C among psychiatric patients in the public sector.  Am J Psychiatry 2003; 160:172–174
[CrossRef] | [PubMed]
 
Batista-Neves  SC;  Quarantini  LC;  de Almeida  AG;  Bressan  RA;  Lacerda  AL;  de-Oliveira  IR;  Paraná  R;  Miranda-Scippa  A:  High frequency of unrecognized mental disorders in HCV-infected patients.  Gen Hosp Psychiatry 2008; 30:80–82
[CrossRef] | [PubMed]
 
Dan  AA;  Crone  C;  Wise  TN;  Martin  LM;  Ramsey  L;  Magee  S;  Sjogren  R;  Ong  JP;  Younossi  ZM:  Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life.  Psychosomatics 2007; 48:223–229
[CrossRef] | [PubMed]
 
Franzen  PL;  Buysse  DJ;  Rabinovitz  M;  Pollock  BG;  Lotrich  FE:  Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment.  Psychiatry Res 2010; 177:240–245
[CrossRef] | [PubMed]
 
Lotrich  FE;  Rabinovitz  M;  Gironda  P;  Pollock  BG:  Depression following pegylated interferon-alpha: characteristics and vulnerability.  J Psychosom Res 2007; 63:131–135
[CrossRef] | [PubMed]
 
Lotrich  FE;  Ferrell  RE;  Rabinovitz  M;  Pollock  BG:  Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha.  Clin Neuropharmacol 2010; 33:191–197
[CrossRef] | [PubMed]
 
Kraus  MR;  Schäfer  A;  Schöttker  K;  Keicher  C;  Weissbrich  B;  Hofbauer  I;  Scheurlen  M:  Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.  Gut 2008; 57:531–536
[CrossRef] | [PubMed]
 
Sockalingam  S;  Abbey  SE:  Managing depression during hepatitis C treatment.  Can J Psychiatry 2009; 54:614–625
[PubMed]
 
Gleason  OC;  Yates  WR;  Philipsen  MA;  Isbell  MD;  Pollock  BG:  Plasma levels of citalopram in depressed patients with hepatitis C.  Psychosomatics 2004; 45:29–33
[CrossRef] | [PubMed]
 
Nickel  T;  Sonntag  A;  Backmund  M;  Pollmächer  T:  Depression during therapy with interferon alpha: how long should an antidepressant treatment last? Pharmacopsychiatry 2005; 38:102–104
[CrossRef] | [PubMed]
 
Capuron  L;  Miller  AH:  Cytokines and psychopathology: lessons from interferon-alpha.  Biol Psychiatry 2004; 56:819–824
[CrossRef] | [PubMed]
 
Martin  KA;  Krahn  LE;  Balan  V;  Rosati  MJ:  Modafinil’s use in combating interferon-induced fatigue.  Dig Dis Sci 2007; 52:893–896
[CrossRef] | [PubMed]
 
Schwartz  AL;  Thompson  JA;  Masood  N:  Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate.  Oncol Nurs Forum 2002; 29:E85–E90
[CrossRef] | [PubMed]
 
Greenberg  DB;  Jonasch  E;  Gadd  MA;  Ryan  BF;  Everett  JR;  Sober  AJ;  Mihm  MA;  Tanabe  KK;  Ott  M;  Haluska  FG:  Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.  Cancer 2000; 89:356–362
[CrossRef] | [PubMed]
 
Onyike  CU;  Bonner  JO;  Lyketsos  CG;  Treisman  GJ:  Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.  Am J Psychiatry 2004; 161:429–435
[CrossRef] | [PubMed]
 
Fattovich  G;  Giustina  G;  Favarato  S;  Ruol  A:  A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.  J Hepatol 1996; 24:38–47
[CrossRef] | [PubMed]
 
Hoffman  RG;  Cohen  MA;  Alfonso  CA;  Weiss  JJ;  Jones  S;  Keller  MB;  Condemarín  JR;  Chiu  N-M;  Jacobson  JM:  Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV.  Psychosomatics 2003; 44:417–420
[CrossRef] | [PubMed]
 
Capuron  L;  Ravaud  A;  Dantzer  R:  Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients.  Psychosom Med 2001; 63:376–386
[PubMed]
 
Malek-Ahmadi  P;  Hilsabeck  RC:  Neuropsychiatric complications of interferons: classification, neurochemical bases, and management.  Ann Clin Psychiatry 2007; 19:113–123
[CrossRef] | [PubMed]
 
Raison  CL;  Woolwine  BJ;  Demetrashvili  MF;  Borisov  AS;  Weinreib  R;  Staab  JP;  Zajecka  JM;  Bruno  CJ;  Henderson  MA;  Reinus  JF;  Evans  DL;  Asnis  GM;  Miller  AH:  Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.  Aliment Pharmacol Ther 2007; 25:1163–1174
[CrossRef] | [PubMed]
 
Prather  AA;  Rabinovitz  M;  Pollock  BG;  Lotrich  FE:  Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality.  Brain Behav Immun 2009; 23:1109–1116
[CrossRef] | [PubMed]
 
Lotrich  FE;  Sears  B;  McNamara  RK:  Elevated ratio of arachidonic acid to long-chain omega-3 fatty acids predicts depression development following interferon-alpha treatment: relationship with interleukin-6.  Brain Behav Immun (Epub ahead of print, Aug 19, 2012)
 
Nicklas  BJ;  Hsu  F-C;  Brinkley  TJ;  Church  T;  Goodpaster  BH;  Kritchevsky  SB;  Pahor  M:  Exercise training and plasma C-reactive protein and interleukin-6 in elderly people.  J Am Geriatr Soc 2008; 56:2045–2052
[CrossRef] | [PubMed]
 
Lambert  CP;  Wright  NR;  Finck  BN;  Villareal  DT:  Exercise but not diet-induced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons.  J Appl Physiol 2008; 105:473–478
[CrossRef] | [PubMed]
 
Bull  SJ;  Huezo-Diaz  P;  Binder  EB;  Cubells  JF;  Ranjith  G;  Maddock  C;  Miyazaki  C;  Alexander  N;  Hotopf  M;  Cleare  AJ;  Norris  S;  Cassidy  E;  Aitchison  KJ;  Miller  AH;  Pariante  CM:  Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.  Mol Psychiatry 2009; 14:1095–1104
[CrossRef] | [PubMed]
 
Raison  CL;  Demetrashvili  M;  Capuron  L;  Miller  AH:  Neuropsychiatric adverse effects of interferon-alpha: recognition and management.  CNS Drugs 2005; 19:105–123
[CrossRef] | [PubMed]
 
Lotrich  FE;  Ferrell  RE;  Rabinovitz  M;  Pollock  BG:  Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism.  Biol Psychiatry 2009; 65:344–348
[CrossRef] | [PubMed]
 
Kraus  MR;  Al-Taie  O;  Schäfer  A;  Pfersdorff  M;  Lesch  KP;  Scheurlen  M:  Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C.  Gastroenterology 2007; 132:1279–1286
[CrossRef] | [PubMed]
 
Su  KP;  Huang  SY;  Peng  CY;  Lai  HC;  Huang  CL;  Chen  YC;  Aitchison  KJ;  Pariante  CM:  Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated faty acids levels.  Biol Psychiatry 2010; 67:550–557
[CrossRef] | [PubMed]
 
Capuron  L;  Raison  CL;  Musselman  DL;  Lawson  DH;  Nemeroff  CB;  Miller  AH:  Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.  Am J Psychiatry 2003; 160:1342–1345
[CrossRef] | [PubMed]
 
Lotrich  FE;  Albusaysi  S;  Ferrell  RE:  Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-alpha treatment.  Neuropsychopharmacology (Epub ahead of print, Dec 18, 2012)
 
Felger  JC;  Alagbe  O;  Pace  TWW;  Woolwine  BJ;  Hu  F;  Raison  CL;  Miller  AH:  Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue.  Brain Behav Immun 2011; 25:1094–1098
[CrossRef] | [PubMed]
 
Juengling  FD;  Ebert  D;  Gut  O;  Engelbrecht  MA;  Rasenack  J;  Nitzsche  EU;  Bauer  J;  Lieb  K:  Prefrontal cortical hypometabolism during low-dose inteferon alpha treatment.  Psychopharmacology (Berl) 2000; 152:383–389
[CrossRef] | [PubMed]
 
Capuron  L;  Pagnoni  G;  Demetrashvili  M;  Woolwine  BJ;  Nemeroff  CB;  Berns  GS;  Miller  AH:  Anterior cingulate activation and error processing during interferon-alpha treatment.  Biol Psychiatry 2005; 58:190–196
[CrossRef] | [PubMed]
 
Capuron  L;  Pagnoni  G;  Demetrashvili  MF;  Lawson  DH;  Fornwalt  FB;  Woolwine  B;  Berns  GS;  Nemeroff  CB;  Miller  AH:  Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.  Neuropsychopharmacology 2007; 32:2384–2392
[CrossRef] | [PubMed]
 
Shuto  H;  Kataoka  Y;  Horikawa  T;  Fujihara  N;  Oishi  R:  Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain.  Brain Res 1997; 747:348–351
[CrossRef] | [PubMed]
 
Abe  S;  Hori  T;  Suzuki  T;  Baba  A;  Shiraishi  H;  Yamamoto  T:  Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain.  Neurochem Res 1999; 24:359–363
[CrossRef] | [PubMed]
 
Capuron  L;  Neurauter  G;  Musselman  DL;  Lawson  DH;  Nemeroff  CB;  Fuchs  D;  Miller  AH:  Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment.  Biol Psychiatry 2003; 54:906–914
[CrossRef] | [PubMed]
 
Dunn  AL;  Crnic  LS:  Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects.  Brain Behav Immun 1993; 7:104–111
[CrossRef] | [PubMed]
 
Wichers  MC;  Maes  M:  The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression.  J Psychiatry Neurosci 2004; 29:11–17
[PubMed]
 
Liu  Y;  Samuel  CE:  Editing of glutamate receptor subunit B pre-mRNA by splice-site variants of interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1.  J Biol Chem 1999; 274:5070–5077
[CrossRef] | [PubMed]
 
Koyanagi  S;  Ohdo  S:  Alteration of intrinsic biological rhythms during interferon treatment and its possible mechanism.  Mol Pharmacol 2002; 62:1393–1399
[CrossRef] | [PubMed]
 
Ho  SB;  Nguyen  H;  Tetrick  LL;  Opitz  GA;  Basara  ML;  Dieperink  E:  Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population.  Am J Gastroenterol 2001; 96:157–164
[PubMed]
 
Goldsmith  J;  Hauser  P:  Psychiatric issues in patients with hepatitis C.  Psychiatr Ann 2003; 33:357–360
 
Mistler  LA;  Brunette  MF;  Marsh  BJ;  Vidaver  RM;  Luckoor  R;  Rosenberg  SD:  Hepatitis C treatment for people with severe mental illness.  Psychosomatics 2006; 47:93–107
[CrossRef] | [PubMed]
 
Hosoda  S;  Takimura  H;  Shibayama  M;  Kanamura  H;  Ikeda  K;  Kumada  H:  Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis.  Psychiatry Clin Neurosci 2000; 54:565–572
[CrossRef] | [PubMed]
 
Asnis  GM;  De La Garza  RI  2nd:  Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches.  J Clin Gastroenterol 2006; 40:322–335
[CrossRef] | [PubMed]
 
Schaefer  M;  Schmidt  F;  Folwaczny  C;  Lorenz  R;  Martin  G;  Schindlbeck  N;  Heldwein  W;  Soyka  M;  Grunze  H;  Koenig  A;  Loeschke  K:  Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.  Hepatology 2003; 37:433–451
[CrossRef]
 
Le Lan  C;  Guillygomarc’h  A;  Danielou  H;  Le Dréau  G;  Lainé  F;  Védeilhié  C;  Deugnier  Y;  Brissot  P;  Guyader  D;  Moirand  R:  A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse.  J Hepatol 2012; 56:334–340
[CrossRef] | [PubMed]
 
Anand  BS;  Currie  S;  Dieperink  E;  Bini  EJ;  Shen  H;  Ho  SB;  Wright  T; VA-HCV-001 Study Group:  Alcohol use and treatment of hepatitis C virus: results of a national multicenter study.  Gastroenterology 2006; 130:1607–1616
[CrossRef] | [PubMed]
 
Neukam  K;  Mira  JA;  Gilabert  I;  Claro  E;  Vázquez  MJ;  Cifuentes  C;  García-Rey  S;  Merchante  N;  Almeida  C;  Macías  J;  Pineda  JA:  Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.  Eur J Clin Microbiol Infect Dis 2012; 31:1225–1232
[CrossRef] | [PubMed]
 
Reichenberg  A;  Gorman  JM;  Dieterich  DT:  Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study.  AIDS 2005; 19(suppl 3):S174–S178
[CrossRef] | [PubMed]
 
Dieperink  E;  Ho  SB;  Thuras  P;  Willenbring  ML:  A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.  Psychosomatics 2003; 44:104–112
[CrossRef] | [PubMed]
 
Hauser  P;  Khosla  J;  Aurora  H;  Laurin  J;  Kling  MA;  Hill  J;  Gulati  M;  Thornton  AJ;  Schultz  RL;  Valentine  AD;  Meyers  CA;  Howell  CD:  A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.  Mol Psychiatry 2002; 7:942–947
[CrossRef] | [PubMed]
 
Schaefer  M;  Schmidt  F;  Horn  M;  Schmid-Wendtner  M-H;  Volkenandt  M:  Depression during treatment with interferon alpha.  Psychosomatics 2004; 45:176
[CrossRef] | [PubMed]
 
References Container
+
+

Self-Assessment Quiz

Did you know? You can add a subscription now to earn CME Credits!

1.
Which of the following is true regarding antidepressant use during interferon-alpha therapy?
2.
Vulnerability to developing depression during interferon-alpha therapy is associated with:
3.
Psychiatric education of the patient prior to starting interferon-alpha therapy should include which of the following:
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 12.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 43.  >
APA Practice Guidelines > Chapter 0.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 47.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 47.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles
Interferon-induced depression in hepatitis C: an update. Curr Psychiatry Rep 2007;9(3):255-61.
Utilizing genomic polymorphisms to personalize hepatitis C therapies. Curr Opin Organ Transplant 2012;17(2):198-203.